An efficient malaria vaccine remains elusive. As an alternative to malaria subunit vaccines,
vaccination approaches are currently explored using live Plasmodium parasites, either …

The Plasmodium falciparum reticulocyte binding protein homologue 5 (PfRH5) has recently
shown great promise to be developed as a vaccine candidate to prevent blood-stage …

Plasmodium falciparum merozoite surface protein (PfMSP) 2 is a target of parasite-
neutralizing Abs. Inclusion of recombinant PfMSP2 (rPfMSP2) as a component of a …

Placental malaria vaccines (PMVs) are being developed to prevent severe sequelae of
placental malaria (PM) in pregnant women and their offspring. The leading candidate …

The Plasmodium falciparum protein VAR2CSA is a critical mediator of placental malaria,
and VAR2CSA antibodies (IgGs) are important to protect pregnant women. Although …

Glycosaminoglycans are often deprioritized as targets for synthetic immunotherapy due to
the complexity of glyco-epitopes and limited options for obtaining specific subtype-binding …

Plasmodium falciparum causes malaria through a complex interaction of parasite-induced
changes in red blood cell (RBC), including microcirculatory abnormalities, immunological …

Pregnant women, the fetus, neonates, and young infants are at an increased risk for serious
diseases from many infections due to their immunocompromised or immunonäive statuses …

Abstract Weltweit leben 3, 1 Mrd. Menschen in Gebieten, in denen Malaria endemisch ist
(Tropen, Subtropen). Jährlich erkranken etwa 200 Mio. Menschen, ca. 500.000 sterben …

Pregnant women are particularly susceptible to Plasmodium falciparum malaria, leading to
substantial maternal and infant morbidity and mortality. While highly effective malaria …